Cancer News
OncoLink Cancer News - HealthDay


FDA Approves Imbruvica for Mantle Cell Lymphoma

Wednesday, November 13, 2013 (Last Updated: 11/14/2013)

WEDNESDAY, Nov. 13 (HealthDay News) -- Imbruvica (ibrutinib) has been approved by the U.S. Food and Drug Administration to treat mantle cell lymphoma (MCL).

MCL represents about 6 percent of non-Hodgkin lymphoma cases, the agency said Wednesday in a news release. By the time it's usually diagnosed, it has spread to other areas such as the lymph nodes or bone marrow.

Imbruvica, designed to inhibit an enzyme that cancer cells need to spread, was granted the FDA's rare "breakthrough therapy" status as a drug that promises to offer a "substantial improvement over available therapies for patients with serious or life-threatening diseases," the agency said.

Imbruvica was evaluated in a study of 111 participants. Of those who took the drug daily, 66 percent had their cancer shrink or disappear, the FDA said. The most common side effects included thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, edema, and upper respiratory infection.

Imbruvica is co-marketed by Sunnyvale, Calif.-based Pharmacyclics, and Raritan, N.J.-based Janssen Biotech.

More Information

Specialties Family Practice
Hematology & Oncology
Gastroenterology
Internal Medicine
Nursing

Health News Copyright © 2013 HealthDay. All rights reserved.


I Wish You Knew

Healthcare Affordability Act

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More